All In Biotech

Drug Trial Radar · NCT07523282

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

A Study to Assess the Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
Collaborators
The First Affiliated Hospital of University of Science and Technology of China
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).

Conditions

  • Autoimmune Disease
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis (SSc)

Interventions

  • HN2302 InjectionDrug

    Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.